PDCD1 and neoplasm: Recent reports showed that the combination of anti-PD-1/PD-L1 therapy with BRAF and MEK inhibitors, VEGF inhibitors, chemotherapy, radiation, and photodynamic therapy would promote tumor-infiltrating T cells and the anti-tumor activity of ICIs [41,42,43,44,45].